Literature DB >> 15261560

Corticosteroids treatment.

Carlo Pozzilli1, Fabiana Marinelli, Silvia Romano, Francesca Bagnato.   

Abstract

Corticosteroids (Cs) are widely used for treatment of multiple sclerosis (MS) acute relapses because of the potent immunosuppressive and anti-inflammatory properties. As for patients with relapsing-remitting (RR) MS, short-term administrations of Cs markedly less severity of symptoms and promote faster recovery of clinical attacks. Chronic administrations of Cs significantly diminish the formation of T1 hypointense lesions and the progression of brain atrophy. As for patients with secondary progressive MS treatment with Cs delays the time to onset of sustained disability. Finally the association between methylprednisolone and interferon beta (IFNbeta) leads the recovery of active lesions at greater extent and reduces the formation of neutralizing antibodies (NABs) against IFNbeta in patients with RRMS. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261560     DOI: 10.1016/j.jns.2004.04.019

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Cerebrovascular hemodynamic changes in multiple sclerosis patients during head-up tilt table test: effect of high-dose intravenous steroid treatment.

Authors:  Zsolt Mezei; Laszlo Olah; Laszlo Kardos; Reka Katalin Kovacs; Laszlo Csiba; Tunde Csepany
Journal:  J Neurol       Date:  2013-06-12       Impact factor: 4.849

2.  Effects of L-carnitine supplementation on biomarkers of oxidative stress, antioxidant capacity and lipid profile, in patients with pemphigus vulgaris: a randomized, double-blind, placebo-controlled trial.

Authors:  H Mohammadi; M Djalali; M Daneshpazhooh; N M Honarvar; C Chams-Davatchi; F Sepandar; Z Fakhri; E Yaghubi; M Zarei; M H Javanbakht
Journal:  Eur J Clin Nutr       Date:  2017-08-23       Impact factor: 4.016

Review 3.  Developing therapeutics for the treatment of multiple sclerosis.

Authors:  David J Virley
Journal:  NeuroRx       Date:  2005-10

4.  Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review.

Authors:  Mazen Abu-Mugheisib; Reiner Benecke; Uwe K Zettl
Journal:  Mult Scler Int       Date:  2011-06-26

5.  Nano-Drugs Based on Nano Sterically Stabilized Liposomes for the Treatment of Inflammatory Neurodegenerative Diseases.

Authors:  Keren Turjeman; Yaelle Bavli; Pablo Kizelsztein; Yaelle Schilt; Nahum Allon; Tamar Blumenfeld Katzir; Efrat Sasson; Uri Raviv; Haim Ovadia; Yechezkel Barenholz
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  Astragaloside IV inhibits microglia activation via glucocorticoid receptor mediated signaling pathway.

Authors:  Hong-Shuai Liu; Hai-Lian Shi; Fei Huang; Karin E Peterson; Hui Wu; Yun-Yi Lan; Bei-Bei Zhang; Yi-Xin He; Tyson Woods; Min Du; Xiao-Jun Wu; Zheng-Tao Wang
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

7.  Preventive treatment with methylprednisolone paradoxically exacerbates experimental autoimmune encephalomyelitis.

Authors:  Simone Wüst; Jens van den Brandt; Holger M Reichardt; Fred Lühder
Journal:  Int J Endocrinol       Date:  2012-11-29       Impact factor: 3.257

8.  Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis.

Authors:  Niklas Beyersdorf; Stefanie Gaupp; Karen Balbach; Jens Schmidt; Klaus V Toyka; Chia-Huey Lin; Thomas Hanke; Thomas Hünig; Thomas Kerkau; Ralf Gold
Journal:  J Exp Med       Date:  2005-08-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.